GlassScriptPhysician profile
Jeffrey B Hargis
NPI 1437122454
$449,831.21
in general payments reported to CMS, 2019-2025
20 companies · $94K in 2025
The $94K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $12K · 2021: $46K · 2022: $87K · 2023: $97K · 2024: $84K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $207K · Travel and Lodging: $32K · Consulting Fee: $30K · Food and Beverage: $4,983 · Long Term Medical Supply Or Device Loan: $167 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $207,090.00 |
| Travel and Lodging | $32,477.25 |
| Consulting Fee | $30,407.50 |
| Food and Beverage | $4,983.36 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $113,145.04 | 2021-2025 | Enhertu, Datroway, Lynparza |
| Gilead Sciences, INC. | $101,376.30 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $83,816.33 | 2020-2025 | Enhertu, Datroway |
| Stemline Therapeutics INC. | $46,727.76 | 2022-2025 | Orserdu |
| Seagen INC. | $29,348.78 | 2020-2023 | Tukysa |
| Pfizer INC. | $21,899.84 | 2019-2020 | |
| Genentech USA, INC. | $20,060.60 | 2019-2023 | Lunsumio |
| Merck Sharp & Dohme LLC | $16,282.55 | 2022-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $8,011.29 | 2019-2023 | |
| Puma Biotechnology, INC. | $4,316.64 | 2023 | Nerlynx |
| Immunomedics, INC. | $2,425.00 | 2020 | |
| Eisai INC. | $1,745.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $235.52 | 2023-2024 | Ultomiris |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Amgen INC. | $99.95 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Macrogenics, INC. | $97.50 | 2021 | |
| Lilly USA, LLC | $43.11 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hargis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.